CSL Ltd (CSL) - Financial and Strategic SWOT Analysis Review
Description
CSL Ltd (CSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
CSL Ltd (CSL) is a biotechnology company. It discovers, develops, manufactures, commercializes and distributes biopharmaceuticals. The company's product portfolio comprises treatments for hemophilia and immune deficiency, vaccines to prevent influenza and therapies for iron deficiency and kidney conditions. CSL's proprietary platform consists of plasma and recombinant protein technology, cell and gene therapy and adjuvant cell-based egg-based mRNA. CSL focuses on conditions related to hematology, respiratory, cardiovascular, metabolic, nephrology and transplant, immunology and vaccines, among others. The company operates in various countries, including Australia, China, Germany, Switzerland, the US, Hungary, Puerto Rico, the UK, Italy, Japan, the Netherlands, and Spain. CSL is headquartered in Melbourne, Victoria, Australia.
CSL Ltd Key Recent Developments
Dec 02,2025: World-Class $1BN Vaccine and Antivenom Manufacturing Facility Opens in Melbourne
Nov 18,2025: CSL To Invest Approximately $1.5B In U.S. To Manufacture Plasma-Derived Therapies
Oct 29,2025: Australian scientists awarded $2.5 million CSL Centenary Fellowships to advance lifelong immunity research and AI-designed proteins
Oct 26,2025: CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
CSL Ltd (CSL) is a biotechnology company. It discovers, develops, manufactures, commercializes and distributes biopharmaceuticals. The company's product portfolio comprises treatments for hemophilia and immune deficiency, vaccines to prevent influenza and therapies for iron deficiency and kidney conditions. CSL's proprietary platform consists of plasma and recombinant protein technology, cell and gene therapy and adjuvant cell-based egg-based mRNA. CSL focuses on conditions related to hematology, respiratory, cardiovascular, metabolic, nephrology and transplant, immunology and vaccines, among others. The company operates in various countries, including Australia, China, Germany, Switzerland, the US, Hungary, Puerto Rico, the UK, Italy, Japan, the Netherlands, and Spain. CSL is headquartered in Melbourne, Victoria, Australia.
CSL Ltd Key Recent Developments
Dec 02,2025: World-Class $1BN Vaccine and Antivenom Manufacturing Facility Opens in Melbourne
Nov 18,2025: CSL To Invest Approximately $1.5B In U.S. To Manufacture Plasma-Derived Therapies
Oct 29,2025: Australian scientists awarded $2.5 million CSL Centenary Fellowships to advance lifelong immunity research and AI-designed proteins
Oct 26,2025: CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
66 Pages
- Section 1 - About the Company
- CSL Ltd - Key Facts
- CSL Ltd - Key Employees
- CSL Ltd - Key Employee Biographies
- CSL Ltd - Major Products and Services
- CSL Ltd - History
- CSL Ltd - Company Statement
- CSL Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- CSL Ltd - Business Description
- Business Segment: CSL Behring
- Overview
- Performance
- Business Segment: CSL Seqirus
- Overview
- Performance
- Business Segment: CSL Vifor
- Overview
- Performance
- Geographical Segment: Australia
- Performance
- Geographical Segment: China and Hong Kong
- Performance
- Geographical Segment: Germany
- Performance
- Geographical Segment: Rest of World
- Performance
- Geographical Segment: Switzerland
- Performance
- Geographical Segment: UK
- Performance
- Geographical Segment: United States
- Performance
- R&D Overview
- CSL Ltd - Corporate Strategy
- CSL Ltd - SWOT Analysis
- SWOT Analysis - Overview
- CSL Ltd - Strengths
- CSL Ltd - Weaknesses
- CSL Ltd - Opportunities
- CSL Ltd - Threats
- CSL Ltd - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- CSL Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- CSL Ltd, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Dec 02, 2025: World-Class $1BN Vaccine and Antivenom Manufacturing Facility Opens in Melbourne
- Nov 18, 2025: CSL To Invest Approximately $1.5B In U.S. To Manufacture Plasma-Derived Therapies
- Oct 29, 2025: Australian scientists awarded $2.5 million CSL Centenary Fellowships to advance lifelong immunity research and AI-designed proteins
- Oct 26, 2025: CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
- Oct 21, 2025: Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
- Oct 17, 2025: CSL’s Near-Term Emissions Reduction Targets Approved by SBTi
- Oct 17, 2025: CSL’s Near-Term Emissions Reduction Targets Validated by the SBTi
- Sep 30, 2025: CSL : Chief Financial Officer Succession
- Aug 18, 2025: CSL Reports Net Profit for 12 Months Ended June 30, 2025
- Jun 10, 2025: CSL Appoints Cameron Price as Independent Non-Executive Director
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- CSL Ltd, Key Facts
- CSL Ltd, Key Employees
- CSL Ltd, Key Employee Biographies
- CSL Ltd, Major Products and Services
- CSL Ltd, History
- CSL Ltd, Other Locations
- CSL Ltd, Subsidiaries
- CSL Ltd, Key Competitors
- CSL Ltd, Ratios based on current share price
- CSL Ltd, Annual Ratios
- CSL Ltd, Annual Ratios (Cont...1)
- CSL Ltd, Annual Ratios (Cont...2)
- CSL Ltd, Interim Ratios
- CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- CSL Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- CSL Ltd, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- CSL Ltd, Performance Chart (2021 - 2025)
- CSL Ltd, Ratio Charts
- CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- CSL Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
